Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $4.35M |
| Net Income (Most Recent Fiscal Year) | $-45.53M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 28.52 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1481.55% |
| Net Margin (Trailing 12 Months) | -1699.86% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -124.27% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.75 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.74 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 12.96 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.78 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.88 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.34 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 108.19M |
| Free Float | 100.83M |
| Market Capitalization | $119.01M |
| Average Volume (Last 20 Days) | 1.39M |
| Beta (Past 60 Months) | 1.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 74.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |